Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gross, W. L.
Right arrow Articles by Reinhold-Keller, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, W. L.
Right arrow Articles by Reinhold-Keller, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 245-252
© 2000 British Society for Rheumatology

Reviews

Diagnosis and evaluation of vasculitis

Vasculitis: Aims of Therapy/Guest Editor: R. Watts

W. L. Gross, A. Trabandt and E. Reinhold-Keller

Department of Clinical Rheumatology, University of Lübeck and Clinic of Rheumatology, Oskar Alexander Strasse 26, 24572 Bad Bramstedt, Germany


   Introduction
 
Vasculitis is inflammation of a vessel wall. The systemic vasculitides represent a highly heterogeneous group of clinicopathological entities. Vasculitis has many causes, although it produces only a few histological patterns of vascular inflammation. The clinical expression depends on the site, type and size of vessels involved. Vessels of any type in any organ can be affected, which is reflected in the wide variety of signs and symptoms. Clinically the systemic vasculitides range from benign, locoregionally restricted processes (e.g. cutaneous leucocytoclastic angiitis) to systemic vasculitis leading to life-threatening conditions [e.g. pulmonary renal syndrome in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis]. Many patients develop their disease against a background of non-specific symptoms, such as malaise, weight loss, fever and night sweats (so-called B-symptoms), which reflect constitutional symptoms. More specific symptoms derive from the type of vessels involved; this has led to the well-known classification scheme of primary systemic vasculitides (Table 1Go). However, . . . [Full Text of this Article]


   Classification
 

   Immunopathogenesis
 

   Immunodiagnostic approach
 

   Diagnosis
 

   Diagnostic route
 

   Notes
 

   References
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Metzler, C. Fink, P. Lamprecht, W. L. Gross, and E. Reinhold-Keller
Maintenance of remission with leflunomide in Wegener's granulomatosis
Rheumatology, March 1, 2004; 43(3): 315 - 320.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Tanaka, J. C. Edberg, W. Chatham, G. Fassina, and R. P. Kimberly
Fc{gamma}RIIIb Allele-Sensitive Release of {alpha}-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of Chemotaxins
J. Immunol., December 1, 2003; 171(11): 6090 - 6096.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. Komocsi, P. Lamprecht, E. Csernok, A. Mueller, K. Holl-Ulrich, U. Seitzer, F. Moosig, A. Schnabel, and W. L. Gross
Peripheral Blood and Granuloma CD4+CD28- T Cells Are a Major Source of Interferon-{gamma} and Tumor Necrosis Factor-{alpha} in Wegener's Granulomatosis
Am. J. Pathol., May 1, 2002; 160(5): 1717 - 1724.
[Abstract] [Full Text] [PDF]